Alcon AG Q1 FY2025 earnings call

Management Statement and Operational Highlights

• Product Launches: Began a cascade of product launches including Unity VCS in Japan and U.S., PanOptix Pro in U.S., PRECISION7, TOTAL30, DAILIES TOTAL1 for astigmatism; Systane Pro expanding in U.S.; Acoltremon PDUFA date end of May; acquired majority in Aurion Biotech and entered into merger agreement to acquire LENSAR.
• Market Dynamics: Global eye care market expected to grow ~4%; U.S. surgical market soft, but international markets solid.
• R&D Investment: Increased investment in R&D, particularly with recent BD&L activity, with core operating margin down 40 basis points primarily due to higher R&D investment.

Segment Performance

• Surgical Franchise: Revenue $1.3 billion, up 2% year-over-year.
• Implantables: Sales $420 million, in line with prior period. Strong growth in advanced technology IOLs in China and international markets, offset by soft U.S. market and competitive pressures.
• Consumables: Sales up 6% to $712 million, driven by vitret and cataract consumables, international markets, and price increases.
• Equipment: Sales $199 million, down 6% year-over-year, but expected to accelerate through the second half of the year with the launch of Unity VCS.
• Vision Care: Sales $1.1 billion, up 3%. Contact lens sales up 4% to $688 million, driven by product innovation and price increases, partially offset by legacy product declines.
• Ocular Health: Sales $432 million, up 2% year-over-year, driven by the sustained family of artificial tears and price, with approximately 3 points of pressure from the divestment of certain eye drops to OcuMension in China.

Guidance

• Updated revenue guidance: $10.4 billion to $10.5 billion, growth 6%-7% in constant currency.
• Core operating margin range: 20%-21%.
• Core diluted earnings guidance: $3.05 to $3.15 per share.
• Dividend approved: CHF0.28 per share, in line with payout policy of 10% of previous year's core net income.

Risks

• Tariffs: Gross impact of ~$80 million for full year, primarily in Q3-Q4, offset by operational actions and currency tailwinds.
• Market Competition: Impact on U.S. cataract market share and growth.
• Regulatory Uncertainties: PDUFA date for Acoltremon and labeling for PanOptix Pro pose regulatory risks.

Q: On tariff impact, quarterly cadence and annual impact?

A: Tariff gross impact ~$80M primarily in Q3-Q4; expect margins to be close to initial guidance, with more color on 2026 if tariffs persist.

Q: On PanOptix Pro launch relative to competitor recall, and PDUFA for Acoltremon?

A: PanOptix Pro launch well received; Acoltremon PDUFA end of May, launch expected late third quarter with limited effect this year.